Shares in this article
Gerresheimer AG78.60 EUR0.13%Show shares in this articleGerresheimer AG78.60 EUR 0.13%Trade here for 0 Show allThis is the beginning of a strategic partnership, he said medical technology company. The joint project includes the development and marketing of the new generation of auto injectors.The two companies want to offer biotech and pharmaceutical customers a so-called one-stop shop for everything to do with auto-injectors: starting with the selection and delivery of the best solution for a medical device and the associated primary packaging, as well as the procurement of the active pharmaceutical ingredients via the entire development up to registration.
Gerresheimer has acquired all rights to the Midas Pharma auto-injector. The new Gerresheimer auto-injector offers biotech and pharmaceutical companies as well as patients new possibilities in the treatment of various diseases. The new generation auto-injector is suitable for subcutaneous injections with an injection volume of up to 3 ml. Financial details of the agreement were not given.
The Gerresheimer share temporarily gained 0.56 percent in XETRA trading to EUR 80.40.
FRANKFURT (Dow Jones)
Selected leverage products on Gerresheimer AG With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable products on Gerresheimer AGLongShortSelect lever:5x10xThe lever must be between 2 and 20LeverKOEmitterTermNo data
How to get the perfect look for Cos...
Test winner at Stiftung Warentest:...
Cream for Rosacea: The Best Creams
Dry elbows: This is how brittle ski...